BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy

被引:37
作者
Dumontet, Charles [1 ]
Krajewska, Maryla [2 ]
Treilleux, Isabelle [1 ]
Mackey, John R. [3 ]
Martin, Miguel [4 ]
Rupin, Mathieu [5 ]
Lafanechere, Laurence [6 ]
Reed, John C. [2 ]
机构
[1] Inst Natl Sante & Rech Med 590, Lyon, France
[2] Burnham Inst Med Res, La Jolla, CA USA
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Hosp Univ San Carlos, Madrid, Spain
[5] Canc Int Res Grp, Paris, France
[6] CEA, Grenoble, France
关键词
HER-2/NEU GENE AMPLIFICATION; ESTROGEN-RECEPTOR; PROTEIN-TAU; PREDICTIVE MARKER; S-PHASE; DOCETAXEL; HER2; EXPRESSION; PACLITAXEL; SENSITIVITY;
D O I
10.1158/1078-0432.CCR-10-0079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: There are currently no validated factors predictive of response to taxanes in patients with breast cancer. We analyzed specimens from patients included in the Breast Cancer International Research Group (BCIRG) 001 trial, a randomized study which showed the superiority of docetaxel/doxorubicin/cyclophosphamide over fluorouracil/doxorubicin/cyclophosphamide as adjuvant therapy for node-positive operable breast cancer in terms of disease-free survival (DFS) and overall survival (OS). Experimental Design: Immunohistochemical assessment of biological markers included histologic grade, tumor size, estrogen and progesterone receptors, lymph node status, HER2, MUC1, Ki-67/MIB-1, p53, Bcl-2, Bax, Bcl-XL, BAG-1, beta-tubulin isotypes II, III and IV, tau protein, and detyrosinated alpha tubulin. Associations between selected parameters and survival were tested through univariate analyses, then completed with multivariate analyses and a bootstrap resampling technique. Results: In univariate analysis histologic grade, tumor size, number of involved nodes, estrogen and progesterone receptor status, p53, Ki-67, tubulin III, and tau protein were associated both with DFS and with OS. In multivariate analysis estrogen and progesterone receptors, tumor size, number of involved nodes, and Ki-67 protein were associated both with DFS and with OS, whereas tau protein levels were correlated with DFS and tubulin III and P53 were correlated with OS. No interaction was observed between Ki-67 and treatment allocation. Conclusions: We conclude that the expression in primary tumors of Ki-67 and p53 protein, as well as of the microtubule-related parameters tau protein and tubulin III, are independent prognostic factors in patients receiving adjuvant chemotherapy for node-positive breast cancer but are not predictive of benefit from docetaxel-containing adjuvant chemotherapy. Clin Cancer Res; 16(15); 3988-97. (C) 2010 AACR.
引用
收藏
页码:3988 / 3997
页数:10
相关论文
共 49 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer [J].
Andre, Fabrice ;
Hatzis, Christos ;
Anderson, Keith ;
Sotiriou, Christos ;
Mazouni, Chafika ;
Mejia, Jaime ;
Wang, Bailang ;
Hortobagyi, Gabriel N. ;
Symmans, W. Fraser ;
Pusztai, Lajos .
CLINICAL CANCER RESEARCH, 2007, 13 (07) :2061-2067
[3]  
[Anonymous], 1993, An introduction to the bootstrap
[4]   Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].
Bear, HD ;
Anderson, S ;
Smith, RE ;
Geyer, CE ;
Mamounas, EP ;
Fisher, B ;
Brown, AM ;
Robidoux, A ;
Margolese, R ;
Kahlenberg, MS ;
Paik, S ;
Soran, A ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2019-2027
[5]   Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer [J].
Berry, DA ;
Cirrincione, C ;
Henderson, IC ;
Citron, ML ;
Budman, DR ;
Goldstein, LJ ;
Martino, S ;
Perez, EA ;
Muss, HB ;
Norton, L ;
Hudis, C ;
Winer, EP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (14) :1658-1667
[6]   Benefit of taxanes as adjuvant chemotherapy for early breast cancer - Pooled analysis of 15,500 patients [J].
Bria, Emilio ;
Nistico, Cecilia ;
Cuppone, Federica ;
Carlini, Paolo ;
Ciccarese, Mariangela ;
Milella, Michele ;
Natoli, Guido ;
Terzoli, Edmondo ;
Cognetti, Francesco ;
Giannarelli, Diana .
CANCER, 2006, 106 (11) :2337-2344
[7]  
Caly M, 2004, ANTICANCER RES, V24, P3283
[8]   Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer [J].
Cheang, Maggie C. U. ;
Chia, Stephen K. ;
Voduc, David ;
Gao, Dongxia ;
Leung, Samuel ;
Snider, Jacqueline ;
Watson, Mark ;
Davies, Sherri ;
Bernard, Philip S. ;
Parker, Joel S. ;
Perou, Charles M. ;
Ellis, Matthew J. ;
Nielsen, Torsten O. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :736-750
[9]  
Depowski PL, 1999, AM J CLIN PATHOL, V112, P459
[10]   Prognostic impact of proliferation associated factors MIBI (Ki-67) and S-phase in node-negative breast cancer [J].
Dettmar, P ;
Harbeck, N ;
Thomssen, C ;
Pache, L ;
Ziffer, P ;
Fizi, K ;
Janicke, F ;
Nathrath, W ;
Schmitt, M ;
Graeff, H ;
Hofler, H .
BRITISH JOURNAL OF CANCER, 1997, 75 (10) :1525-1533